Clinical Use of Biomarkers in Cardiac Amyloidosis

Abstract

Amyloidosis is a systemic condition characterized by multiple organs involvement. A multidisciplinary and multimodal approach in assessing patients is pivotal and recommended by the international scientific societies. Biomarkers represent an essential noninvasive tool to increase the suspicion of disease and orient further workup and clinical management of patients. This review provides an updated contemporary focus on the clinical use of biomarkers in cardiac amyloidosis, emphasizing their role in both the diagnostic and prognostic setting and discussing future perspective of emerging biomarkers.

Keywords: Amyloidosis; Biomarkers; Diagnosis; Light chains; Prognosis; Transthyretin; Treatment.